论文网
枸橼酸方面有关毕业论文格式模板,关于局部枸橼酸抗凝在重症医学科连续性肾脏替代治疗中的应用相关毕业论文格式模板范文
这是一篇枸橼酸方面有关毕业论文格式模板范文,与局部枸橼酸抗凝在重症医学科连续性肾脏替代治疗中的应用相关毕业论文格式模板。是医药学专业与枸橼酸及肝素及重症医学方面相关的免费优秀学术论文范文资料，可作为枸橼酸方面的大学硕士与本科毕业论文开题报告范文和职称论文论文写作参考文献下载。
.[7] Balik M,Zakharchenko M,Leden P,et al. Bioenergetic gain of citrate anticoagulated continuous hemodiafiltration-a parison between 2 citrate modalities and unfractionated heparin [J]. J Crit Care,2013,28（1）：87-95.
[8] Balik M,Zakharchenko M,Otahal M,et al. Quantification of systemic delivery of substrates for intermediate metabolism during citrate anticoagulation of continuous renal replacement therapy [J]. Blood Purif,2012,33（1）：80-87.
[9] Oudemans SH,Kellum JA,Bellomo R. Clinical review：anticoagulation for continuous renal replacement therapy-heparin or citrate? [J]. Crit Care,2011,15（1）：202.
[10] Mehta RL,McDonald BR,Aguilar MM,et al. Regional citrate anticoagulation for continuous arteriovenous haemodialysis in critically ill patients [J]. Kidney Int,1990,38（5）：976-981.
[11] 龚德华,季大玺,徐斌,等.枸橼酸钠抗凝在重危患者连续性血液净化的应用[J].中华内科杂志,2003,42（2）：121-122.
[12] Meier HU,Gitomer J,Finkel K,et al. Increased total to ionised calcium ratio during continuous venovenous haemodialysis with regional citrate anticoagulation [J]. Crit Care Med,2001,29（2）：748-752.
[13] Saner F,Treckmann J,Geis A,et al. Efficacy and safety of regional citrate anticoagulation in liver transplant patients requiring post-operative renal replacement therapy [J]. Nephrol Dial Transplant,2012,27：1651-1657. [14] Kramer L,Bauer E,Joukhadar C,et al. Citrate pharmacokiics and metabolism in cirrhotic and noncirrhotic critically ill patients [J]. Crit Care Med,2003,31（10）：2450-2455.
[15] Rasheed A,Balogun FT,Stephen C, et al. Iii patients with liver and kidney failure [J]. Jnephrol,2012,25（1）：113-119.
[16] 郑寅,许钟烨,焦正,等.连续性肾脏替代治疗时枸橼酸药物代谢动力学数学模型的构建[J].中华肾脏病杂志,2010,26（6）：432-437.
[17] Zhang Z,Hongying N. Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy [J]. Intensive Care Med,2012,38（1）：20-28.
[18] Bos JC,Grooteman MP,van HA,et al. Low polymorphonuclear cell degranulation during citrate anticoagulation：a parison between citrate and heparin dialysis [J]. Nephrol Dial Transplant,1997,12（7）：387-1393.
[19] Hofbauer R,Moser D,Frass M,et al. Effect of anticoagulation on blood membrane interactions during hemodialysis [J]. Kidney Int,1999,56（4）：1578-1583.
[20] Monchi M,Berghmans D,Ledoux D,et al. Citrate vs heparin for anticoagulation in continuous venovenous hemofiltration：a prospective randomized study [J]. Intensive Care Med,2004,30（2）：260-265.
[21] Betjes MG,Van OD,Van AM,et al. Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding：similar hemofilter survival but significantly less bleeding [J]. Nephrol,2007,20：602-608.
[22] Oudemans SH,Bosman RJ,Koopmans M,et al. Citrate anticoagulation for continuous venovenous hemofiltration [J]. Crit Care Med,2009,37（2）：545-552.
[23] Wu M,Hsu Y,Bai C,et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy：a meta-analysis of randomized controlled trials [J]. Am J Kidney Dis,2012,59：810-818.
[24] Hetzel GR,Schmitz M,Wissing H,et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration：a prospective randomized multicentre trial [J]. Nephrol Dial Transplant,2011,26：232-239.
[25] Oudemans SH,Fiaccadori,Baldwin I. Anticoagulation for renal replacement therapy：different methods to improve safety.Practice of renal replacement therapy in the ICU：cardiorenal syndromes in critical care [J]. Contrib Nephrol,2010,165,251-262.
[26] Mera S,Schneider M,Slowinski T,et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status [J]. Crit Care Med,2009,37：2018-2024. [27] Kutsogiannis DJ,Gibney RT,Stollery D,et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients [J]. Kidney Int,2005,67：2361-2367.
[28] Mera S,Haase M,Ruckert M,et al. Regional citrate anticoagulation in continuous hemodialysis-acid-base and electrolyte balance at an increased dose of dialysis [J]. Nephron Clin Pract,2005,101：c211-c219.
[29] Tolwani AJ,Prendergast MB,Speer RR,et al. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance [J]. Clin J Am Soc Nephrol,2006,1（1）：79-87.
[30] Nurmohamed SA,Vervloet MG,Girbes AR,et al. Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation：a prospective study[J]. Blood Purif,2007,25（4）：316-323.
[31] Shum HP,Chan KC,Yan WW. Regional citrate anticoagulation in predilution continuous venovenous hemofiltration using prismocitrate 10/2 solution [J]. Ther Apher Dial,2012,16：81-86.
[32] Mariano F,Morselli M,Bergamo D,et al. Blood and ultrafiltrate dosage of citrate as a useful and routine tool during continuous venovenous haemodiafiltration in septic shock patients[J]. Nephrol Dial Transplant,2011,26（12）：3882-3888.
[33] Link A,Klingele M,Speer T,et al. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients [J]. Crit Care,2012,16（3）：97.
[34] Claure GR,Macedo E,Chertow GM,et al. Toward the optimal dose metric in continuous renal replacement therapy [J]. Int J Artif Organs,2012,35（6）：413-424.
[35] Morabito S,Pistolesi V,Tritapepe L,et al. Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding：a continuous veno-venous hemofiltration protocol with a low concentration citrate solution [J]. Crit Care,2012,16（2）：111.
[36] Schultheiss C,Saugel B,Phillip V,et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure：a prospective observational study [J]. Crit Care,2012,16（4）：162.
[37] Davenport A,Gardner C,Delaney M,et al. The effect of dialysis modality on phosphate control：haemodialysis pared to haemodiafiltration. The Pan Thames Renal Audit [J]. Nephrol Dial Transplant,2010,25（3）：897-901.
[38] Legrand M,Darmon M,Joannidis M,et al. Management of renal replacement therapy in ICU patients：an international survey [J]. Intensive Care Med,2013,39：101-108.
[39] Davenport A,Tolwani A. Citrate anticoagulation for continuous renal replacement therapy（CRRT）in patients with acute kidney injury admitted to the intensive care unit [J]. Nephrol Dial Transplant Plus,2009,2：439-447.
[40] 张凯悦,徐斌,吴丛业,等.局部枸橼酸联合小剂量低分子肝素抗凝在连续性肾脏替代治疗中的应用[J].肾脏病与移植杂志,2012,21（4）：311-316.
（收稿日期：2013-11-02 本文编辑：任 念）
枸橼酸方面有关毕业论文格式模板,关于局部枸橼酸抗凝在重症医学科连续性肾脏替代治疗中的应用相关毕业论文格式模板范文参考文献：
重症医学科护理论文
:(盖章),医院名称血液透析室(中心)重症医学科血液透析机数量医师数量护理人员,数量床位数量呼吸机数量。医学院学生毕业论文广西 第一临床医学院中医关于200级本科生撰写毕业论文的通。
康复医学科
医师定期考核管理办法实施细则科,肾内科,儿科,耳鼻喉科,康复医学科,重症医学科,超声诊断科等专业.,职称学历要求:副主任医师以上职称,硕士研究生以上学历,其中主任医师,博士研究。
心身医学科
医学科护理学类专着,妇科类着作,儿科类着作,诊断类专着,方剂类专着,针灸类着作,医案,医话类着作,综合型着作等17类文献.约180本,现代医学期刊30余本,其中包括《实用中医内。
重症医学论文
重症医学高级职称武汉米,扣5分;少于4平方米不得分.3支撑,条件,(30)相关科室能够满足专科发展需要△10现场核实,查重症医学科,麻醉科,医学影像科等的诊治能力各科医疗技术队。
计算机在会计中的应用论文
计算机应用,管理系统中计算机应用《管理系统中计算机应用》,考试大纲,编,山东经济学院,2016年1月, 目录,第一部分理论考试大纲1,一,课程性质及课程设置的目的和要求1,。09。
重症医学高级职称
重症医学高级职称武汉"科研与教学"占100分.,标准中的相关技术指标,如无特别注明,均指评估时上一年度的数据.,标准中部分指标内容可累积计分,但最后得分不超过标准分.,学科带头。
重症护理论文
室(中心)重症医学科血液透析机数量医师数量护理人员,数量床位数量呼吸机数量。护理论文中医升了服务品质,赢得了患者的赞誉.她们科先后被评为蚌埠市"优质护理服务示范工程"先进科室,安徽省。
重症医学中级
重症医学高级职称武汉米,扣5分;少于4平方米不得分.3支撑,条件,(30)相关科室能够满足专科发展需要△10现场核实,查重症医学科,麻醉科,医学影像科等的诊治能力各科医疗技术队。
gps在工程测量中的应用论文
关于工程测量工程测量中的应用,7.3gps定位技术在地球动力学研究中的应用,7.4gps定位技术在海洋测绘中的应用,7.5gps定位技术在精密工程测量和工程变形监测中的应用,7。
重症手足口病的护理
6平方米得10分;每减少1平方。重症医学高级职称考试广东附件1,县医院部分专科医疗资源现状调查表,市卫生局:(盖章),医院名称血液透析室(中心)重症医学科血液透析机数量医师数量护理人。